Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study

被引:56
作者
Walker, Venexia M. [1 ,2 ]
Kehoe, Patrick G. [3 ,4 ]
Martin, Richard M. [1 ,2 ]
Davies, Neil M. [1 ,2 ]
机构
[1] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England
[2] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England
[3] Univ Bristol, Dementia Res Grp, Bristol, Avon, England
[4] Univ Bristol, Bristol Med Sch Translat Hlth Sci, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
Mendelian randomization; drug repurposing; Alzheimer's disease; hypertension; antihypertensive drugs; BLOOD-PRESSURE; INSTRUMENTS; RISK;
D O I
10.1093/ije/dyz155
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. Methods: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. Results: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p= 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p= 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p= 0.45; SNPs = 153). Conclusions: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 37 条
  • [1] Genetic effects on gene expression across human tissues
    Aguet, Francois
    Brown, Andrew A.
    Castel, Stephane E.
    Davis, Joe R.
    He, Yuan
    Jo, Brian
    Mohammadi, Pejman
    Park, Yoson
    Parsana, Princy
    Segre, Ayellet V.
    Strober, Benjamin J.
    Zappala, Zachary
    Cummings, Beryl B.
    Gelfand, Ellen T.
    Hadley, Kane
    Huang, Katherine H.
    Lek, Monkol
    Li, Xiao
    Nedzel, Jared L.
    Nguyen, Duyen Y.
    Noble, Michael S.
    Sullivan, Timothy J.
    Tukiainen, Taru
    MacArthur, Daniel G.
    Getz, Gad
    Management, Nih Program
    Addington, Anjene
    Guan, Ping
    Koester, Susan
    Little, A. Roger
    Lockhart, Nicole C.
    Moore, Helen M.
    Rao, Abhi
    Struewing, Jeffery P.
    Volpi, Simona
    Collection, Biospecimen
    Brigham, Lori E.
    Hasz, Richard
    Hunter, Marcus
    Johns, Christopher
    Johnson, Mark
    Kopen, Gene
    Leinweber, William F.
    Lonsdale, John T.
    McDonald, Alisa
    Mestichelli, Bernadette
    Myer, Kevin
    Roe, Bryan
    Salvatore, Michael
    Shad, Saboor
    [J]. NATURE, 2017, 550 (7675) : 204 - +
  • [2] UK Biobank Data: Come and Get It
    Allen, Naomi E.
    Sudlow, Cathie
    Peakman, Tim
    Collins, Rory
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
  • [3] A global reference for human genetic variation
    Altshuler, David M.
    Durbin, Richard M.
    Abecasis, Goncalo R.
    Bentley, David R.
    Chakravarti, Aravinda
    Clark, Andrew G.
    Donnelly, Peter
    Eichler, Evan E.
    Flicek, Paul
    Gabriel, Stacey B.
    Gibbs, Richard A.
    Green, Eric D.
    Hurles, Matthew E.
    Knoppers, Bartha M.
    Korbel, Jan O.
    Lander, Eric S.
    Lee, Charles
    Lehrach, Hans
    Mardis, Elaine R.
    Marth, Gabor T.
    McVean, Gil A.
    Nickerson, Deborah A.
    Wang, Jun
    Wilson, Richard K.
    Boerwinkle, Eric
    Doddapaneni, Harsha
    Han, Yi
    Korchina, Viktoriya
    Kovar, Christie
    Lee, Sandra
    Muzny, Donna
    Reid, Jeffrey G.
    Zhu, Yiming
    Chang, Yuqi
    Feng, Qiang
    Fang, Xiaodong
    Guo, Xiaosen
    Jian, Min
    Jiang, Hui
    Jin, Xin
    Lan, Tianming
    Li, Guoqing
    Li, Jingxiang
    Li, Yingrui
    Liu, Shengmao
    Liu, Xiao
    Lu, Yao
    Ma, Xuedi
    Tang, Meifang
    Wang, Bo
    [J]. NATURE, 2015, 526 (7571) : 68 - +
  • [4] [Anonymous], 2019, JAMA
  • [5] Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
    Appleby, Brian S.
    Cummings, Jeffrey L.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (18) : 2306 - 2327
  • [6] Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression
    Bowden, Jack
    Smith, George Davey
    Burgess, Stephen
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2015, 44 (02) : 512 - 525
  • [7] Burgess S, ARXIV201504486
  • [8] Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
    Burgess, Stephen
    Butterworth, Adam
    Thompson, Simon G.
    [J]. GENETIC EPIDEMIOLOGY, 2013, 37 (07) : 658 - 665
  • [9] FROM THE ANALYST'S COUCH What does it take to produce a breakthrough drug?
    Calcoen, Dirk
    Elias, Laura
    Yu, Xiaomeng
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (03) : 161 - 162
  • [10] Drug repositioning for Alzheimer's disease
    Corbett, Anne
    Pickett, James
    Burns, Alistair
    Corcoran, Jonathan
    Dunnett, Stephen B.
    Edison, Paul
    Hagan, Jim J.
    Holmes, Clive
    Jones, Emma
    Katona, Cornelius
    Kearns, Ian
    Kehoe, Patrick
    Mudher, Amrit
    Passmore, Anthony
    Shepherd, Nicola
    Walsh, Frank
    Ballard, Clive
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) : 833 - 846